Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study of the Effect of NeoRecormon on Reduction of Cardiovascular Risk in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy.

NCT00321919 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00321919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00321919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study of the Effect of NeoRecormon on Reduction of Cardiovascular Risk in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2000
Completion date
December 31, 2004
Enrollment
605 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

anemia